Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 45 clinical trials
Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors

The aim of this single-arm phase 2 clinical trial is to evaluate the anti-cancer activity of Talazoparib (also known as BMN 673) in patients with advanced breast cancer with specific genetic or

immunohistochemistry
advanced breast cancer
mammogram
her2-negative breast cancer
carboplatin
  • 5 views
  • 08 Sep, 2021
  • 1 location
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

This research is to evaluate the effectiveness of Talazoparib as a potential treatment for metastatic breast cancer with a BRCA 1 or BRCA 2 mutation.

hormone therapy
endocrine therapy
metastasis
erbb2
triple negative breast cancer
  • 6 views
  • 17 Sep, 2022
  • 4 locations
Talazoparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response

Background People with advanced cancer are usually treated with surgery, radiation, immunotherapy drugs, or chemotherapy drugs. Talazoparib is a type of drug

  • 0 views
  • 13 Jan, 2021
  • 1 location
A Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the DNA Polymerase Theta Inhibitor ART4215 Administered Orally as Monotherapy and in Combination to Patients With Advanced or Metastatic Solid Tumors

ART4215 that can be given safely to participants alone and in combination with talazoparib Learn more about the side effects of ART4215 alone and in combination with talazoparib Learn

mammogram
taxane
core needle biopsy
BRCA1
BRCA2
  • 0 views
  • 18 Sep, 2022
  • 6 locations
A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer (TARA)

This is a Phase II study designed to assess efficacy and safety of talazoparib, high dose radiation, and atezolizumab in patients with metastatic TNBC that is PD-L1 positive. A total of 23 gBRCA

mammogram
progesterone receptor
estrogen
triple negative breast cancer
erbb2
  • 0 views
  • 25 Jul, 2022
  • 2 locations
A Randomized Phase I/II Study of Talazoparib or Temozolomide in Combination With Onivyde in Children With Recurrent Solid Malignancies and Ewing Sarcoma

talazoparib. Onivyde works by damaging the DNA of the cancer cell and talazoparib works by blocking the repair of the DNA once the cancer cell is damaged. By damaging the tumor DNA and blocking the repair

  • 0 views
  • 19 Sep, 2022
  • 1 location
Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination With Talazoparib in Patients With SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)

This phase II trial studies whether atezolizumab in combination with talazoparib works better than atezolizumab alone as maintenance therapy for patients with SLFN11-positive extensive-stage

leptomeningeal disease
immunodeficiency
cns disease
prophylactic cranial irradiation
monoclonal antibodies
  • 0 views
  • 19 Sep, 2022
  • 391 locations
A Phase Ib/II Study of Intermittent Talazoparib Plus Temozolomide in Subjects With Metastatic Castration Resistant Prostate Cancer and No Mutations in DNA Damage Repair

The purpose of this study is to determine what the safest dose of talazoparib plus temozolomide for participants with metastatic castration resistant prostate cancer.

androgens
gilbert's syndrome
potassium
ct scan
medical castration
  • 9 views
  • 19 Aug, 2022
  • 8 locations
Phase 2 Trial of the Combination of the BET Inhibitor, ZEN003694 (ZEN-3694), and the PARP Inhibitor Talazoparib, in Patients With Molecularly-Selected Solid Tumors (ComBET)

This phase II trial tests whether ZEN003694 (ZEN-3694) in combination with talazoparib works to shrink tumors in patients with solid tumors that are unlikely to be cured or controlled with

  • 0 views
  • 17 Sep, 2022
  • 1 location
Phase 1 Trial of PARP Inhibitor Combined With 177Lu-DOTA-Octreotate Peptide Receptor Radionuclide Therapy (PRRT) in Patients With Metastatic NeuroEndocrine Tumor (PARLuNET)

This phase 1 dose-escalation study is designed to evaluate the safety and tolerability of talazoparib in combination with 177Lu-DOTA-Octreotate peptide receptor radionuclide therapy (PRRT) in

  • 0 views
  • 18 Sep, 2022
  • 1 location